A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Conditions : Malignant Tumors Interventions : Drug: LM-364 for injection; Drug: Tislelizumab Sponsors : LaNova Medicines Limited Not yet recruiting
Read the full article16h agoen
You might also wanna read
ClinicalKey
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim ove
clinicalkey.com·1mo ago
Una combinación de medicamentos dirigidos produce remisiones duraderas en las personas con linfoma de células B de crecimiento rápido resistente al tratamiento
Los tumores de más de la mitad de los participantes que recibieron tratamiento con venetoclax, ibrutinib, prednisona, obinutuzumab y lenalid
NCI·2y ago
Disitamab Vedotin, Tislelizumab, and S-1 Deliver High Response Rates in HER2-Overexpressing Advanced Gastric/GEJ Cancer
HER2-targeted therapy has improved outcomes in advanced gastric and gastroesophageal junction adenocarcinoma, but resistance and heterogeneo
OncoDaily·1h ago
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Phase 1 trial of ABBV-706 in 288 patients with advanced solid tumors reveals potential in SCLC: 240 on monotherapy, 124 with RR-SCLC. PMID:4
doi.org·7d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.